Will ADMA report Q1 2026 revenue above $130M?

ADMA quarterly revenue trajectory shows clear momentum: Q1 2025 ~$117M, Q2 ~$118M, Q3 ~$136M, Q4 $139.2M. The $130M threshold is below Q3 and Q4 2025 actuals. For Q1 2026 to miss $130M, revenue would need to decline ~7% sequentially from Q4 and ~4% from Q3. Given ASCENIV 51% YoY growth trajectory and Yield Enhancement first full year, a sequential decline of this magnitude would require significant channel digestion. While some pull-forward is plausible, a drop below $130M seems unlikely given the product momentum. FY2026 guidance of >$635M implies ~$159M/quarter average.

The short seller channel stuffing claim would imply Q4 revenue was artificially inflated and Q1 would show a hangover. However, even the short seller claimed only a -3% revenue decline (which would put FY2025 around $412M vs reported $510M). The committee found this claim implausible given ASCENIV documented clinical differentiation. Channel loading is plausible to some degree -- maybe 5-10% of Q4 revenue was timing-related -- but $130M is a low bar. Even with some Q1 softness, ASCENIV structural demand (PI patients need ongoing treatment) provides a floor. The McKesson transition could create brief ordering disruption.

I focus on the medical product dynamics. ASCENIV treats primary immunodeficiency, a chronic condition requiring ongoing infusions. Patient enrollment is sticky and growing. Published clinical data (Tan et al.) shows genuine efficacy advantage. Payer coverage for ASCENIV is expanding, not contracting. These fundamentals support sustained revenue above $130M even if there is some quarterly timing noise. The risk is primarily in the BioCare/CuraScript ordering pattern. But $130M is low enough that even a weak Q1 should exceed it.

The $130M bar is set well below current quarterly performance ($136M Q3, $139M Q4). For ADMA to miss this, revenue would need to contract 7% sequentially, which would be highly unusual for a biologic with expanding patient enrollment and new manufacturing capacity. ASCENIV patient starts do not reverse quarter-to-quarter because this is not a discretionary purchase. Even if some channel loading occurred in Q4, the underlying patient demand provides a floor well above $130M. Management $635M+ FY2026 guide is aggressive, but $130M/quarter is the minimum implied by FY2025 run rate.

The key question is whether channel stuffing at BioCare/CuraScript was significant enough to cause a >$10M sequential decline. Even if 10% of Q4 revenue ($14M) was pulled forward, Q1 base would be around $125M + organic growth. The organic growth from ASCENIV adoption and Yield Enhancement should add at least $5-10M to Q1 versus Q1 2025 ($117M). This puts Q1 2026 in the $125-135M range as a reasonable estimate. $130M is in the middle of this range, making exceedance probable but not certain.

ADMA Q1 2025 was ~$117M. Even flat sequential from Q4, Q1 2026 YoY growth of only 11% ($130M) would be dramatically below the 20% full-year FY2025 growth rate and the 51% ASCENIV growth. This implies that $130M+ requires minimal execution. The real risk scenario is extreme channel stuffing (>15% of Q4 revenue pulled forward) combined with McKesson transition disruption. This tail scenario is possible but unlikely given the committee consensus that ASCENIV demand is genuine.

$130M threshold is below Q3 and Q4 2025 actuals. ASCENIV patient demand is chronic and sticky. FY2026 guidance implies much higher quarterly average. Even with some channel digestion, $130M+ is likely. Clear lean YES.

The bar is set low. Q1 2025 was ~$117M and the company was growing 20%+ YoY. Even with channel digestion, Q1 2026 should be well above Q1 2025. Some risk from McKesson transition disruption and timing effects. $130M is achievable with even modest growth.

ASCENIV clinical differentiation is genuine per committee consensus. 51% YoY ASCENIV growth provides strong tailwind. $130M requires only 11% YoY growth, which is very achievable. Channel stuffing risk exists but unlikely to cause a >7% sequential decline. Probable YES.